静脉-静脉体外膜氧合中血小板减少的发生率、动力学及临床影响:多中心观察性PROTECMO研究的启示
PROTECMO多中心前瞻性观察研究纳入652例因呼吸衰竭接受VV ECMO的成人患者,按血小板计数分为轻度(100-149×10⁹/L)、中度(50-99×10⁹/L)和重度(<50×10⁹/L)血小板减少,采用改良出血学术研究联盟评分评估出血事件。基线时27.9%患者存在血小板减少,ECMO期间至少一次发生血小板减少者达80.2%。血小板计数每降低10×10⁹/L,出血风险增加3.7%(95%CI 2.4-5.0%),轻、中、重度血小板减少分别使出血风险增加61%、约90%和约90%。ECMO期间血小板<100×10⁹/L的风险随ECMO前ICU天数、术后入院、免疫抑制状态、肾脏替代治疗、脓毒性休克、低血红蛋白和管路更换而显著增加。
要点
- VV ECMO期间至少一次发生血小板减少者占80.2%,其中轻度21.3%、中度32.2%、重度26.7%。
- 血小板计数每降低10×10⁹/L,出血风险增加3.7%(95%CI 2.4-5.0%),在25,000-300,000范围内无明显非线性关系。
- 轻度血小板减少(100-149×10⁹/L)增加出血风险61%(HR 1.611,95%CI 1.230-2.109,p=0.0005)。
- 中度(50-99×10⁹/L)和重度(<50×10⁹/L)血小板减少分别增加出血风险约90%(HR 1.944,95%CI 1.484-2.545;HR 1.876,95%CI 1.275-2.768,p=0.0014)。
- ECMO期间血小板<100×10⁹/L的风险随ECMO前ICU天数、术后入院、免疫抑制、肾脏替代治疗、脓毒性休克、低血红蛋白和管路更换显著增加。
适用人群与场景
- 因呼吸衰竭接受VV ECMO的成人患者(多中心前瞻性观察性PROTECMO研究纳入652例)。
诊断标准与关键阈值
- 血小板减少分级:轻度100-149×10⁹/L,中度50-99×10⁹/L,重度<50×10⁹/L。
- 出血事件采用改良出血学术研究联盟评分评估。
研究设计与关键结果
- 多中心前瞻性观察性研究纳入652例VV ECMO成人患者;基线血小板减少27.9%(轻度14.7%、中度8.7%、重度4.4%),ECMO期间至少一次80.2%(轻度21.3%、中度32.2%、重度26.7%)。
- 血小板计数每降低10×10⁹/L,出血风险增加3.7%(95%CI 2.4-5.0%),在25,000-300,000范围内无强非线性关系证据,且各ECMO周保持一致。
- 轻度血小板减少增加出血风险61%(HR 1.611,95%CI 1.230-2.109,p=0.0005);中度增加约90%(HR 1.944,95%CI 1.484-2.545,p<0.0001);重度增加约90%(HR 1.876,95%CI 1.275-2.768,p=0.0014)。
- ECMO期间血小板<100×10⁹/L的风险随ECMO前ICU天数、术后入院、免疫抑制状态、肾脏替代治疗、脓毒性休克、低血红蛋白和管路更换显著增加。
- 血小板减少与6个月生存率降低相关,尤其血小板<100×10⁹/L时。
证据类型、等级与局限
- 证据类型:多中心前瞻性观察性研究(PROTECMO研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为需要进一步研究以更好地定义血小板输注特定阈值相关的结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Thrombocytopenia is a recognized risk factor for bleeding during extracorporeal membrane oxygenation (ECMO). This study determines the incidence, risk factors, and clinical relevance of thrombocytopenia and platelet transfusions during venovenous (VV) ECMO.
METHODS: The multicenter, prospective observational PROTECMO study included 652 adult patients who received VV ECMO for respiratory failure. Thrombocytopenia was classified as mild (100-149·109/L), moderate (50-99·109/L), or severe (< 50·109/L). Bleeding events were evaluated using a modified Bleeding Academy Research Consortium score. Cox proportional hazards and logistic regression analyses were done to identify predictors, and quantify the association between platelet counts and bleeding risk.
RESULTS: A total of 182 patients (27.9%) had thrombocytopenia at baseline (mild in 14.7%, moderate in 8.7%, and severe in 4.4%). Thrombocytopenia during ECMO, at least once in 80.2% of patients, was mild in 21.3% of cases, moderate in 32.2%, and severe in 26.7%. A 10·109/L decrease in platelet count was associated with a 3.7% (95% CI: 2.4-5.0%) increase in risk of bleeding. There was no strong evidence of nonlinear relationship within the platelet count range between 25,000 and 300,000. This relation remained consistent across all ECMO weeks. Mild thrombocytopenia increased the risk of experiencing a bleeding event by 61% (hazard ratio (HR) 1.611, 95% CI 1.230-2.109, p = 0.0005), while moderate and severe thrombocytopenia increased the risk by roughly 90% (moderate: HR 1.944 (CI 1.484-2.545), p < 0.0001; severe: HR 1.876 (CI 1.275-2.7680), p = 0.0014). The risk for thrombocytopenia < 100·109/L during ECMO significantly increased with ICU days prior to ECMO start, postoperative admission, immunocompromised state, renal replacement therapy, septic shock, low hemoglobin, and circuit exchange.
CONCLUSIONS: Thrombocytopenia is highly prevalent in VV ECMO, and associated with a significant increase in the risk of bleeding, and a reduction in 6-month survival, particularly at platelet counts below 100·109/L. Further research is needed to better define the outcomes associated with specific thresholds for transfusion of platelets.
参考来源
- Buchtele N, Tanaka K, Tuzzolino F, et al. Incidence, kinetics, and clinical impact of thrombocytopenia in venovenous ECMO: insights from the multicenter observational PROTECMO study. Crit Care. 2025. PMID: 40775790. doi:10.1186/s13054-025-05569-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。